The clinical monitoring of disease activity and drug compatibility could be further enhanced by wearable devices that track physical parameters and by noninvasive biomarker monitoring (eg, c-reactive protein or interleukin-1 for IBD from sweat [79]). This evidence concerns the gene CRP and irritable bowel syndrome.